• DENTSPLY SIRONA Inc. (NASDAQ:XRAY) faces an investigation for potential violations of federal securities laws, affecting its stock price.
• The company's decision to suspend sales of Byte Aligners and Impression Kits led to a significant stock price drop.
• Despite recent challenges, a notable director's investment suggests potential confidence in the company's future.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) is under investigation by Kessler Topaz Meltzer & Check, LLP for potential violations of federal securities laws. The investigation was triggered by DENTSPLY's announcement on October 24, 2024, to voluntarily suspend sales and marketing of its Byte Aligners and Impression Kits. This decision was made in consultation with the FDA as the company reviews regulatory requirements for these products.

Following the announcement, DENTSPLY's stock price fell by $1.10 per share, or 4.51%, closing at $23.31 on October 25, 2024. This decline has prompted investors who suffered significant losses to seek more information from Kessler Topaz Meltzer & Check, LLP, a firm renowned for prosecuting securities fraud class actions and recovering billions for investors worldwide.

On November 18, 2024, Gregory T. Lucier, a director at XRAY, purchased 5,000 shares of common stock at approximately $18.37 each. This transaction increased his total ownership to 71,730 shares. The stock is currently priced at $19.05, marking a 3.20% increase or $0.59. The stock has fluctuated between $18.14 and $19.09 during the day.

Over the past year, XRAY's stock has seen a high of $37.60 and a low of $17.21, with a market capitalization of about $3.79 billion. Today's trading volume on the NASDAQ exchange is 2,046,314 shares. This activity reflects ongoing investor interest and market reactions to recent developments surrounding the company.